References
1 Abdel Shaheed C, Beardsley J, Day RO, McLachlan AJ. Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: Mechanisms and relevance to infection. British Journal of Clinical Pharmacology.
2 Chen JS, Alfajaro MM, Wei J, Chow RD, Filler RB, Eisenbarth SC, Wilen CB. Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication. BioRxiv. 2020 Sep 25.
3 de Bruin N, Schneider AK, Reus P, Talmon S, Ciesek S, Bojkova D, Cinatl J, Lodhi I, Charlesworth B, Sinclair S, Pennick G. Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. International Journal of Molecular Sciences. 2022 Jan;23(3):1049.
4 Terrier O, Dilly S, Pizzorno A, Chalupska D, Humpolickova J, Bouřa E, Berenbaum F, Quideau S, Lina B, Fève B, Adnet F. Antiviral properties of the NSAID drug naproxen targeting the nucleoprotein of SARS-CoV-2 coronavirus. Molecules. 2021 Jan;26(9):2593.
5 Saleh E, Moody MA, Walter EB. Effect of antipyretic analgesics on immune responses to vaccination. Human vaccines & immunotherapeutics. 2016 Sep 1;12(9):2391-402.
6 Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020 Aug 15;396(10249):467-78.
7 Ooi EE, Dhar A, Petruschke R, Locht C, Buchy P, Low JG. Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. npj Vaccines. 2022 Mar 2;7(1):1-0.